Press Centre
Press Releases
Board Update and Director´s Dealing
Phynova Group plc
("Phynova" or the "Company")
Board update and director´s dealing
Phynova (AIM: PYN), a leading botanical drug development company, today announces a restructuring of its board of directors, with immediate effect. The board changes are being made following the resignation of the Executive Chairman and a review of the business.
Robert Miller, currently a director of the Company and Chief Executive Officer of Phynova China Limited, has been re-appointed Chief Executive Officer of the Company. In addition, Tony Mills, currently a director of the Company and Chief Executive Officer of Phynova Limited, has been appointed Chief Commercial Officer of the Company. Michael Martin will continue as part-time Chief Financial Officer.
Following the changes set out above, the board will comprise Steve Harris (Non-Executive Chairman), Robert Miller (Chief Executive Officer), Dr Tony Mills (Chief Commercial Officer), Michael Martin (part-time Chief Financial Officer) and Dr Jin Li (Non-Executive Director).
The Company also announces that Robert Miller has today gifted 383,333 ordinary shares, equivalent to 1.22 per cent. of the Company´s issued share capital, to Ms Alice Lyon. Following the transfer of these shares, Mr Miller now holds 745,853 ordinary shares, equivalent to 2.37 per cent. of the voting share capital. Ms Lyon does not have a notifiable interest in the Company.
For further information, please contact:
Phynova Group PLC +44 (0) 1993 880700
Steve Harris (Non-Executive Chairman)
Robert Miller (Chief Executive Officer)
Tony Mills (Chief Commercial Officer)
John East & Partners Limited +44 (0) 20 7628 2200
John East/Simon Clements
Notes to Editors:
About Phynova
Phynova is a UK company developing new prescription pharmaceuticals derived from plants used in Chinese medicines. The Company is focused on viral and bacterial diseases, metabolic diseases and cancer. Phynova´s lead product for hepatitis C has now completed a Phase I/II trial in the US. One further product, for post-operative ileus, is targeted for entry to the clinic and there are a further four products in preclinical development.
For further information please visit www.phynova.com.
05/06/2009
<< Back | See all current Press releses